Contribute Try STAT+ Today

People living with amyotrophic lateral sclerosis, or ALS, in the U.S. will have to wait longer than their counterparts in Europe and Canada for access to a potentially beneficial treatment, even though the medicine is being developed here.

Patient advocates have responded by accusing the Food and Drug Administration of ignoring the desperate needs of people with ALS and reneging on commitments to speed the approval of new medicines to treat the fatal, neuro-degenerative disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is beyond outrageous. Unjustifiable. The FDA has gradually been losing respect among researchers and doctors. This tops their other brainless, heartless decisions.
    Is the FDA afraid of side effects? These patients only wish they could put their demise on hold for “2-3 years” while you diddle about with your data and statistics.

Comments are closed.